Experimental
studies using suitable animal models for spinal cord injury (SCI) help to
simulate clinical conditions as observed in humans and play an important role
to understand the pathophysiology of the disease and to develop effective
treatment modalities. To date no satisfactory drug treatment or other methodsof interventions like physiotherapeutically related rehabilitation process havebeen designed to repair the traumatically injured spinal cord in humans. The
aim of the present study is to understand the behavioral recovery that often
occurs following the initial primary injury, and to develop suitable
rehabilitative intervention including pharmacological agent to enhance improved
sensory and motor function. Furthermore, this research intends to bring
awareness among the nurses working in general wards, specialized wards, and
occupational health set-ups, to understand the need to show their passion for
SCI patient’s care by exploring and learning standardized and improvised
rehabilitation methods to manage and practice effective nursing caring skills
for SCI patients.
Tacrolimus
(also known as FK506), a macrolide lactane antibiotic, was introduced as an
immunosuppressive agent with virtually no side effects. Tacrolimus, a potent
calcineurin inhibitor exhibits neuroprotection actions in several experimental
models of central nervous system trauma, including stroke and improved
neurological recovery following peripheral and spinal cord injuries. However,
some side effects from oral and intravenous administration of Tacrolimus in
clinical case studies have been reported which include nephrotoxicity, lung
damage, various neuropsychiatric problems, neurotoxic effects such as akinetic
mutism and catatonic mutism. On the contrary, in experimental studies,
Tacrolimus improves the functional outcome of spinal cord injury and has an in
vivo neurotrophic action whereby it enhances the rate of axon regeneration
leading to more rapid neurological recovery.(Read more)
No comments:
Post a Comment